Deprescribing antihypertensive drugs after starting OSA primary therapy?

Sleep. 2022 May 12;45(5):zsac060. doi: 10.1093/sleep/zsac060. Epub 2022 Mar 25.

Bruno Revol^{1

2

3}, Christel Castelli^{4

5}, Raoua Ben Messaoud^{1

2}, Amandine Coffy⁵, Sébastien Bailly^{1

2}, Ingrid Jullian-Desayes^{1

2}, Jean-Benoît Martinot^{6

7}, Pierre Martinot^{6

7}, Marie Joyeux-Faure^{1

2}, Jean-Louis Pépin^{1

2}

¹ HP2 Laboratory, Inserm U1300, Grenoble Alpes University, Grenoble, France.
² EFCR Laboratory, Pole Thorax and Vessels, Grenoble Alpes University Hospital, Grenoble, France.
³ Pharmacovigilance Department, Grenoble Alpes University Hospital, Grenoble, France.
⁴ UMR 5815, Laboratory of Law and Health Economics, University of Montpellier, Montpellier, France.
⁵ Department of Languedoc Mutualité Nouvelles Technologies, Montpellier Beausoleil Clinic, Montpellier, France.
⁶ Sleep Laboratory, CHU UCL Namur Site Sainte-Elisabeth, Namur, Belgium.
⁷ Institute of Experimental and Clinical Research, UCL, Bruxelles Woluwe, Belgium.

No abstract available

Publication types